TTY Biopharm Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	3.5yrs
Board average tenure	7.9yrs

Recent management updates

Recent updates

Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

Apr 02

Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?

Mar 15

Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?

Feb 25

TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Feb 07

TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially

Jan 19

What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jan 10

TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

Dec 15

How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?

Nov 25

CEO

TTY Biopharm has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Yung-Min Chiang	Chief Financial Officer & Chief Auditor	less than a year	no data	no data
Shu-Wen Wang	Accounting Officer	8.8yrs	no data	no data
Shu-Fen Huang	Chief Legal & Compliance Officer	2.1yrs	no data	no data
Wei-Ying Yin	Director of Public Affairs Department	no data	no data	no data
Jen-Yang Chang	Chief Human Resource Officer	5yrs	no data	no data
Si-Yuan Yang	Senior Vice President	15yrs	no data	no data
Allen Chu	Head of Intensive Care Business Unit	no data	no data	no data
Ching-Lan Hou	General Manager	2.1yrs	no data	no data

3.5yrs

Average Tenure

Experienced Management: 4105's management team is considered experienced (3.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Tze-Kaing Yang	Director	7.9yrs	no data	no data
Chuan-Quan Lin	Chairman of the Board	12.9yrs	no data	0.080% NT$ 15.4m
Ming-Ling Hsueh	Independent Director	7.9yrs	no data	no data
Wen-Hwa Chang	Vice Chairman	28.8yrs	no data	7.56% NT$ 1.4b
Hsiu-Chi Chang	Director	7.9yrs	no data	no data
Ying-Ying Liao	Director	7.9yrs	no data	no data
Duei Tsai	Independent Director	7.9yrs	no data	no data
Tien-Fu Ling	Independent Director	7.9yrs	no data	no data
Carl Hsiao	Representative Director	5.2yrs	no data	0.35% NT$ 68.0m

7.9yrs

Average Tenure

68yo

Average Age

Experienced Board: 4105's board of directors are considered experienced (7.9 years average tenure).

TTY Biopharm Management

Management criteria checks 2/4

Key information

Recent management updates

TTY Biopharm Company Limited Announces Change of CFO and Financial Officer

TTY Biopharm Company Limited, Annual General Meeting, May 30, 2024

Less than half of directors are independent

TTY Biopharm Company Limited Announces Internal Audit Officer Changes, Effective November 7, 2022

Less than half of directors are independent

TTY Biopharm Company Limited Announces the Resignation of Chou,Te-Yu as Member of Remuneration Committee

Recent updates

TTY Biopharm Company Limited to Report Q1, 2024 Results on May 07, 2024

Upcoming dividend of NT$3.50 per share

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Dividend increased to NT$3.50

TTY Biopharm Company Limited Announces Change of CFO and Financial Officer

TTY Biopharm Company Limited, Annual General Meeting, May 30, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 10% to NT$86.00

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations

Price target increased by 14% to NT$84.50

TTY Biopharm Company Limited Announces Decision Rendered by the Supreme Court for Validity of the Risperidone Development Agreement Between the Company and Center Laboratories, Inc

Now 20% undervalued after recent price drop

Upcoming dividend of NT$3.40 per share at 4.3% yield

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to NT$71.50

Price target increased to NT$79.50

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

TTY Biopharm Company Limited Announces Internal Audit Officer Changes, Effective November 7, 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of NT$3.00 per share

TTY Biopharm Company Limited Announces Dividend Distribution, Payable on August 15, 2022

TTY Biopharm Company Limited Announces Cash Dividend for the Year 2021

Price target decreased to NT$73.00

Less than half of directors are independent

TTY Biopharm Company Limited Announces the Resignation of Chou,Te-Yu as Member of Remuneration Committee

Price target decreased to NT$73.67

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Third quarter 2021 earnings released: EPS NT$1.02 (vs NT$0.90 in 3Q 2020)

Upcoming dividend of NT$4.00 per share

Price target increased to NT$80.00

Consensus EPS estimates fall to NT$2.87

Second quarter 2021 earnings released: EPS NT$0.13 (vs NT$0.75 in 2Q 2020)

Price target increased to NT$80.20

Price target increased to NT$80.20

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS NT$0.82 (vs NT$1.02 in 1Q 2020)

Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

Tty Biopharm Company Limited Proposes Dividend for the Period January 1, 2020 to December 31, 2020

Full year 2020 earnings released: EPS NT$3.72 (vs NT$3.62 in FY 2019)

Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?

PAION AG Enters into License Agreement with TTY Biopharm Company Limited

Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?

Price target lowered to NT$73.50

TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

TTY Biopharm Company Limited, Annual General Meeting, Jun 09, 2021

New 90-day low: NT$61.40

TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially

New 90-day low: NT$68.10

What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?

TTY Biopharm Company Limited Announces Executive Changes, with Effect from January 20, 2021

Revenue and earnings beat expectations

Third quarter 2020 earnings released: EPS NT$0.89

Market bids up stock over the past week

New 90-day high: NT$84.30

Analysts lower revenue estimates to NT$4.14b

New 90-day low: NT$66.20

Price target lowered to NT$79.33

New 90-day low - NT$68.70

First half earnings released

First half earnings released

CEO

Leadership Team

Average Tenure

Board Members